The Food and Drug Administration today required certain COVID-19 test developers to evaluate how SARS-CoV-2 mutations impact their test’s performance and update the labeling for the product accordingly. The new conditions for emergency use authorization pertain to certain authorized molecular, antigen and serological tests.
 

Related News Articles

Blog
Understanding potential costs is an important part of the patient experience when planning for care, and hospitals and health systems are committed to helping…
Headline
An initial 10 million doses of COVID-19 vaccine are available for children under age 5 if the Food and Drug Administration authorizes and the Centers for…
Headline
Abbott has recalled certain lots of its Dragonfly OpStar imaging catheter because a marker band may separate from the catheter and remain in the patient after…
Headline
AHA today urged the Federal Trade Commission to scrutinize commercial health plans that steer patients to third-party specialty pharmacies in which they have a…
Headline
The Food and Drug Administration last week extended to 24 months the shelf life for certain lots of refrigerated bamlanivimab. The combination monoclonal…
Headline
Medtronic this week alerted health care providers to a defect in its Heartware Ventricular Assist Device System that may cause the internal pump to malfunction…